While additional research is required to evaluate the drug's side effects and those of similar GLP-1R agonists, these findings form the basis for developing the next generation of anti-weight-gain therapeutics
Heres the formal language from the guidelines, For people with type 2 diabetes and chronic kidney disease with albuminuria treated with maximum tolerated doses of ACE inhibitor or angiotensin receptor blocker, the addition of finerenone is recommended to improve cardiovascular outcomes and reduce the risk of chronic kidney disease progression
Bhatt DL, et al
However, slowed stomach emptying may lead to numerous gastrointestinal side effects, such as nausea, bloating, indigestion, diarrhea, and constipation
1,2 This review evaluates the proposed mechanisms of action of GLP-1RAs, critically analyses recent evidence from clinical trials and considers the optimal clinical use of GLP-1RAs and potential future directions